bioAffinity reports 300% YoY CyPath Lung sales growth in April; partners with Philips for veteran screening

bioAffinity Technologies, Inc.

CyPath Lung unit sales in April 2026 increased nearly 300% vs. April 2025; ordering physician sites up 69% Q1 2025 to Q1 2026.
Collaboration with Philips to enhance lung cancer screening for U.S. veterans using mobile CT, CyPath Lung, and 4DMedical software.
Pilot study with Brooke Army Medical Center underway for asthma/COPD companion diagnostics using flow cytometry+AI.
Preclinical research shows siRNA silencing selectively kills squamous skin cancer cells, suggesting topical treatment for basal/squamous cell carcinomas.
Recent news includes Mexico patent allowance for CyPath Lung technology and record monthly sales in April 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.